Lindus Therapeutics

Next-generation drug development

Lindus advances portfolios of in-licensed assets through our integrated trial platform, collaborating with biotech and pharma to take medicines further, faster.

$80 million
total funding
45+
completed trials across broad therapeutic areas
80
team size across the US and Europe
82%
of Lindus trials completed enrollment on or ahead of timeline
[1]
[1] Measured against all 28 trials that completed enrollment within the past 3 years, where Lindus was responsible for enrollment.
About us

Leveraging our trial execution capability
to advance portfolios of assets

Lindus was originally founded as a technology-first clinical research organization. We have now expanded into asset development, leveraging our trial delivery capability. Lindus runs faster, higher quality clinical trials using technology to automate manual processes, recruit patients directly, and provide real-time access to data.

Global trial execution

Execution spanning the US, UK, and Europe, with integrated APAC partnerships

World Map Update Lindus
Core presence
Integrated partnership
Why Lindus

A partner that can execute on what
you've built

01
Proven in-house trial execution

A track record of delivering trials on time and on budget across 45+ phase I-IV studies. Your asset is developed by the same team that designs and executes the trial — keeping ClinOps, data management, and medical oversight fully aligned in-house.

02
Faster timeline to readout

Central patient enrollment infrastructure combines AI-powered EHR searching, digital pre-screening, and patient concierge. This reduces screen failures and compresses enrollment timelines. Our trial platform enables faster close-out and data analysis.

03
Flexible trial designs

Our clinical trial technology platform and international footprint support a wide range of study designs. From multi-country protocols and multi-indication programs to adaptive designs, we build the trial around what the program needs.

Team and advisors

Leadership with deep operational and
scientific expertise

Leadership

Meri Beckwith
Co-Founder and CEO
Former life sciences and healthtech venture capital investor. Co-founded Lindus to prove that technology could help deliver better, faster clinical trials. MSc Biology, University of Oxford.
Michael Young
Co-Founder
Michael was previously a Special Adviser to the UK Prime Minister, where he advised on a range of issues including life sciences. Before serving in government, he worked at McKinsey & Company and L.E.K. Consulting, predominantly on commercialization and M&A in the healthcare space. His time in government during the pandemic showed him how much trial delivery depended on fragmented, outdated infrastructure, and convinced him the industry needed a fundamentally different operating model; without this none of the groundbreaking advances in understanding human biology will ever benefit patients. He founded Lindus to fix these bottlenecks.
Dr. Luke Twelves
CMO
Luke is a physician with nearly three decades of clinical and leadership experience. He was Lindus employee number three. He previously served as CEO of Omnes Healthcare, delivering dermatology, ENT, diagnostic, and general practice services to the NHS, and directed clinical governance at UnitedHealth Group (Optum). He continues to practise as a GP alongside his role at Lindus, bringing frontline clinical perspective to the medical oversight of every trial. He trained at the Universities of Oxford and Cambridge, and holds an MBA from Durham University.
Sean Sheppard
VP Corporate Development
Sean has built his career on the investment and dealmaking side of clinical-stage biopharma. Before Lindus, his most recent role was at AtaiBeckley (acquired by Lilly), a neuropsychiatry company, where he led end-to-end transactions across M&A, licensing, academic collaborations, and equity investments. He has also served on the boards of multiple clinical-stage biopharma companies, in both Director and Observer roles. He began his career at L.E.K. Consulting, advising biopharma, pharma services, and private equity clients on corporate strategy and due diligence. He holds a BA and an MSc in Natural Sciences from the University of Cambridge.
Gemma Harrison
CPTO
Gemma leads R&D of Citrus, Lindus’ AI-assisted operating system. She is a technology executive who has spent her career building and scaling engineering teams. Before Lindus she spent three years as a Principal Software Engineering Manager at Microsoft, leading teams of up to 30 engineers on Telecoms products in Azure. Prior to that she spent 23 years at Metaswitch Networks, advancing from Software Engineer to Senior Software Engineering Manager. She holds a BA in Mathematics and a Diploma in Computer Science from the University of Cambridge, and is an active advocate for women in technology.

Advisors

Dr. Robert Langer
Strategic Advisor
Robert S. Langer, ScD, co-founded Moderna and over 40 other biopharma companies. He holds 1,400+ patents licensed to 400+ pharmaceutical, biotech, and medical device companies, and is one of three living individuals to have received both the US National Medal of Science and the National Medal of Technology and Innovation. He is an Institute Professor at MIT — the institution's highest faculty honour — and a member of the Koch Institute for Integrative Cancer Research. He is the most cited engineer in history, with over 1,600 published papers.
Dr. Tim Garnett
Strategic Advisor
Tim spent 23 years at Eli Lilly, serving as Chief Medical Officer and Senior Vice President from 2008 to 2021. He oversaw regulatory affairs, patient safety, and clinical development across the US, Europe, China, and Japan, and led the global development of duloxetine across depression, pain, and incontinence indications. He also managed the raloxifene (EVISTA) programme in women's health. He currently chairs the board of Ophirex and serves as a board member for MapLight Therapeutics and Cardiol Therapeutics.
Dr. Alessandro Falcone
Strategic Advisor
Alessandro is a medical doctor and life sciences executive currently serving as Regional Head of JLABS Singapore for Johnson & Johnson. At AstraZeneca, he served as Executive Director of Breast Cancer Oncology R&D Clinical Development Strategy, leading clinical programmes for three marketed oncology therapies: Enhertu, Lynparza, and Imfinzi. He previously held R&D leadership roles at GSK and strategy roles at Novartis. He holds an MBBS from UCL and an MSc in Experimental and Translational Therapeutics from the University of Oxford.
Our approach

Deal structures that work for both sides



Lindus structures deals to work for our partners from signing through clinical and commercial milestones. Terms are designed around what fits the asset and your goals.

We are flexible about deal types, whether that means exclusive or non-exclusive licenses, territory splits, option agreements, joint ventures, or co-development.

Exclusive global license
Option agreements
Ex-APAC licenses
Co-development
SpinCo / Joint ventures

Geographic footprint

With a full time team of over 80, our footprint covers North America and Western Europe, with capability to enroll sites & patients in select additional countries.

World Map Dark Mode Lindus
Core presence
Integrated partnership

In the news

This is some text inside of a div block.
This is some text inside of a div block.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.